News
21 August, 2026
A milestone worth celebrating at Nasdaq Stockholm
Friday marked a special moment for Disruptive Pharma, as colleagues, Board members and guests gathered at Nasdaq Stockholm to celebrate the company's new chapter as a listed company. The opening bell ceremony was an opportunity to reflect on how far Disruptive Pharma and Formulite® have come – from many years of scientific research and...
During summer 2026, Disruptive Pharma welcomed Johannes Schwarz, a Master's student at Uppsala University, to our labs in Uppsala through the SweDeliver Summer Internship programme. During his internship, Johannes explored how different formulations influence the tableting process and the properties of the final tablets. The project provided...
11 June, 2026
CEO update: Disruptive Pharma and Formulite®
In this Swedish-language presentation, CEO Peter Åsberg gives an update on Disruptive Pharma, the company’s proprietary Formulite® technology platform, and the next phase of development. Watch the presentation on YouTube: https://www.youtube.com/watch?v=IWPt4QuAQG8&t=87s
In this Swedish-language interview, Disruptive Pharma and Guard Therapeutics discuss the proposed reverse takeover announced on 10 June 2026, including the background to the transaction and what the planned combination could mean for Disruptive Pharma's continued development. Watch the interview on YouTube: https://www.youtube.com/watch?v=nYjn5G9jffY&t=74s...
At the DDF Summit 2026 in Berlin, Disruptive Pharma presented an award-winning poster on Formulite®, our bioavailability enhancement platform for poorly soluble oral drugs. The poster, which won the 2026 Poster Competition, summarizes technical and clinical validation data, including improved dissolution, higher drug loading, bioavailability...